This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Express Scripts Study Reveals Keys To Controlling Specialty Drug Costs





WASHINGTON, March 7, 2013 /PRNewswire/ -- A study presented today at the National Business Group on Health's (NBGH) Business Health Agenda 2013 conference in Washington, D.C., showed that, on average, employers that use multiple cost management programs had a 50 percent lower specialty drug trend than employers that did not use any specialty management programs.

(Logo:  http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO)

The study, conducted by Express Scripts (NASDAQ: ESRX), is one of the first to examine the impact of multiple utilization management programs on the cost of specialty medications — a cost that is expected to account for $1 out of every $4 spent on prescription medications by 2014.

"Specialty drug costs and use have escalated without sufficient oversight to manage waste or misuse of these expensive medications. Add in the impact of bad health decisions and you get both poor financial and clinical outcomes," said Glen Stettin, MD, senior vice president, Clinical, Research & New Solutions, Express Scripts. "This data clearly demonstrates that multiple progressive management solutions mitigate the rising cost of specialty therapies by identifying and seizing cost-saving opportunities, as well as enabling better decisions that can lead to improved health outcomes."

Many key factors contribute to the rising costs of specialty medications for complex diseases such as cancer, hepatitis C and multiple sclerosis, including price inflation, increasing utilization and new drug introductions. In some cases, these medications can cost upwards of $100,000 per person per year.

Express Scripts researchers analyzed the specialty drug spending of 60 employer clients who are members of NBGH, representing more than 5 million Americans with pharmacy benefits. The employers were categorized into one of three groups based on the type of cost management programs adopted:

  • Unmanaged — employers whose health plan members could obtain their specialty medications from any pharmacy and did not use any specialty utilization management programs
  • Somewhat managed — employers whose health plan members used a specialty pharmacy exclusively and one specialty utilization management program
  • Tightly managed — consisting of employers whose health plan members used a specialty pharmacy exclusively combined with multiple specialty utilization management programs

Employers classified as unmanaged experienced an annual average increase in specialty drug spending per member per year of 27.8 percent. However, employers classified as tightly managed saw an annual increase in specialty drug spending per member per year of 13.6 percent, half that of the unmanaged group and nearly one-third lower than the average annual projected specialty drug trend. In addition, tightly managed programs saw higher average member adherence rates in top therapy classes such as multiple sclerosis and oncology.

Stock quotes in this article: ESRX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs